Moderated Poster

Poster, Podium & Video Sessions

MP18-11: Exploring the clinical uptake and use of PSMA PET MRI hybrid imaging in prostate cancer patients at an academic center in Australia

Friday, May 12
3:30 PM - 5:30 PM
Location: BCEC: Room 153

Presentation Authors: Andre Joshi*, Cheryl Nicholson, Handoo Rhee, Ian McKenzie, Janelle Munns, Greg Malone, Eric Chung, Malcolm Lawson, Peter Heathcote, John Preston, Simon Wood, Sonja Gustafson, Ken Miles, Ian Vela, Brisbane, Australia

Introduction: Positron emission tomography (PET) using prostate specific membrane antigen (PSMA) detects prostate cancer lesions with a higher sensitivity and specificity when compared to standard imaging. Hybrid PET Magnetic Resonance Imaging (MRI) has now been introduced to provide potentially improved characterization of lesions with added PET avidity. We evaluate the utilization of this novel imaging modality at the Princess Alexandra Hospital (PAH) and assess our initial outcomes.

Methods: A retrospective review of all PSMA PET MRI scans undertaken at the PAH since the introduction of the technology was performed. Imaging data was collected alongside baseline clinical data, PSA, previous histology, previous treatments, indication of scans, requesting clinicians and clinical outcomes.

Results: A total of 187 PSMA PET MRI scans were performed at the PAH from April 2015 to October 2016. The median age of imaged patients was 68, with a median PSA of 6ng/ml and Gleason score of 7 at the time of scan. 153 scans were positive for PSMA avid disease (81.8%). Scans were requested in the setting of biochemical recurrence (n=94), preoperative staging (n=77), evaluation of treatment response (n=11) and diagnostic purposes (n=5). Urologists requested PSMA PET MRI most frequently with 111 scans, of which 58.6% requested for preoperative staging. Radiation oncologists requested 69 scans with 75.4% of these in the biochemical recurrence setting. Only 7 scans were requested by medical oncologists. Amongst patients with biochemical recurrence the lowest PSA of a positive scan was 0.02 ng/ml. In this group 43 patients had prior surgery with 19 positive scans (44%). 51 patients were treated with ADT and or EBRT and 46 had positive scans (90.2%). 29 patients had tissue samples to validate PSMA PET MRI. 26 patients (89.7%) had adenocarcinoma on histology correlating with avid lesions on PSMA PET.

Conclusions: PSMA PET MRI has had rapid uptake in use since introduction at the PAH. Urologists and radiation oncologists appear to utilize this imaging modality most; Urologists for a preoperative "one stop shop" staging study and radiation oncologists in biochemical recurrence. From this data is also appears that a positive PSMA PET/MRI is highly suggestive of prostate cancer, with a specificity of 89.7%. Hybrid PET/MRI may be used to stage men locally and systemically with one scan, with lower radiation and at PSA ≤1 ng/ml. This modality has the potential to significantly improve prostate cancer staging and allow early identification of recurrent disease.

Source Of Funding: None

Andre Joshi, MBBS

APCRC-Q, Princess Alexandra Hospital, Translational Research Institute

Dr Andre Joshi MBBS, MAppSc (Res) Candidate
I am a Junior Doctor and Clinical Researcher as part of the Australian Prostate Cancer Research Centre Queensland (APCRC-Q), the QIMR Berghofer Medical Research Institute and the Princess Alexandra Hospital Urology department in Australia. I have an interest in Urological oncology and precision medicine.

Presentation(s):

Send Email for Andre Joshi


Assets

MP18-11: Exploring the clinical uptake and use of PSMA PET MRI hybrid imaging in prostate cancer patients at an academic center in Australia



Attendees who have favorited this

Send Email for Exploring the clinical uptake and use of PSMA PET MRI hybrid imaging in prostate cancer patients at an academic center in Australia